ReviewFrontiers in oncology2026
Beyond fibrosis: the molecular roadmap from MASLD to hepatocellular carcinoma.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) has overtaken viral hepatitis as the fastest-growing cause of hepatocellular carcinoma (HCC) in most high-income countries. What makes this epidemic clinically treacherous is a feature that distinguishes MASLD-related HCC from other aetiologies: roughly half of all cases arise in livers that have never progressed to cirrhosis, slipping through the net of conventional surveillance strategies. The molecular journey from fatty liver to malignancy unfolds through at least six interlocking programmes: lipotoxic rewiring of hepatocyte metabolism, including acquired lysosomal acid lipase (LAL) dysfunction, oncogenic glucose reprogramming through the p53-PUMA-mitochondrial pyruvate carrier (MPC) axis, and a preliminary MLKL-Mfn2 axis linking metabolic stress to mitochondrial dysfunction; a chronic shift in the hepatic immune milieu toward tumour-permissive tolerance; gut microbiota dysbiosis flooding portal circulation with pro-inflammatory metabolites; progressive collapse of autophagic flux with p62/SQSTM1 accumulation and lipolysosome formation; and pervasive epigenetic rewriting spanning DNA methylation, novel histone marks, and non-coding RNA networks. We also discuss emerging biomarkers and therapeutic strategies, closing with a brief note on Doublecortin-like kinase 1 (DCLK1) as a candidate marker at the intersection of cancer stem cell identity and immune microenvironment subversion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.